Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Receptos initiates clinical trials for S1P1 agonist program, aimed at multiple sclerosis
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Novel therapies for memory cells in autoimmune diseases.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
Analysis of Onset Mechanisms of a Sphingosine 1-Phosphate Receptor Modulator Fingolomod-Induced Atrioventricular Conduction Block and QT-Interval Prolongation.
Ofatumumab Dose-finding in RRMS Patients
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Reactive astrocytes as therapeutic targets for CNS disorders.
Persistence on therapy and propensity matched outcome comparison of two subcutaneous interferon Beta 1a dosages for multiple sclerosis.
Patient reported outcome measures in neurogenic bladder.
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Cortical demyelination and diffuse white matter injury in multiple sclerosis.
Copolymer-1 promotes neurogenesis and improves functional recovery after acute ischemic stroke in rats.
Study hints of rituximab MS benefit
BRIEF-Health Canada approves Genzyme's Aubagio to treat relapsing remitting multiple sclerosis
Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Nephritis
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Mitoxantrone for multiple sclerosis.
The two faces of neuromyelitis optica.

Pages